Cervomed announces topline data from rewind-lb phase 2b clinical trial in patients with dementia with lewy bodies

—neflamapimod did not demonstrate statistically significant effects versus placebo on primary and secondary endpoints at 16 weeks—

CRVO Ratings Summary

CRVO Quant Ranking